The plasminogen activation system in rheumatoid arthritis

Fibrinolysis

Volumn 10, Issue SUPPL. 2, 1996, Pages 95-98

  Ronday, H K ^a,b   Breedveld, F C ^b   Verheijen, J H ^a  

^a TNO   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR 1;

CONFERENCE PAPER; FIBRINOLYSIS; HUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

EID: 0029949107     PISSN: 02689499     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-9499(96)80059-2     Document Type: Conference Paper

References (38)

1. Krane S M, Conca W, Stephenson M L et al 1990 Mechanisms of matrix degradation. Ann NY Acad Sci 580: 340-345
2. Inman R D, Harpel P C 1986 α2-Plasmin inhibitor-plasmin complexes in synovial fluid. J Rheumatol 13: 535-537
3. Kikuchi H, Tanaka S, Matsuo O 1987 Plasminogen activator in synovial fluid from patients with rheumatoid arthritis. J Rheumatol 14: 439-445
4. Kummer J A, Abbink J J, De Boer J P et al 1992 Analysis of intraarticular fibrinolytic pathways in patients with inflammatory and noninflammatory joint diseases. Arthritis Rheum 35: 884-893
5. Saxne T, Lecander I. Geborek P 1993 Plasminogen activators and plasminogen activator inhibitors in synovial fluid. Difference between inflammatory joint disorders and osteoarthritis. J Rheumatol 20: 91-6
6. Brommer E J P, Dooijewaard G, Dijkmans BAC, Breedveld F C 1992 Depression of tissue-type plasminogen activator and enhancement of urokinase-type plasminogen activator as an expression of local inflammation. Thromb Haemostas 68: 180-184
7. Ronday H K, Smits H H, van Muijen G N P, et al 1996 Difference in expression of the plasminogen activation systerr in synovial tissue of patients with rheumatoid arthritis and osteoarthritis. Br J Rheumatol 35: accepted for publication
8. Campbell I K, Picolli D S, Roberts M J, Muirden K D, Hamilton J A 1990 Effects of tumor necrosis factor α and β on resorption of human articular cartilage and production of plasminogen activator by human articular chondrocytes. Arthritis Rheum 33: 542-552
9. Medcalf R L, Hamilton J A 1986 Human synovial fibroblasts produce urokinase-type plasminogen activator. Arthritis Rheum 29: 1397-1401
10. Kirchheimer J C Remold H G, Wanivenhaus A, Binder B R 1991 Increased proteolytic activity on the surface of monocytes from patients with rheumatoid arthritis. Arthritis Rheum 34: 1430-1433
11. Hamilton J A, Hart P H, Leizer T, Vitti G F, Campbell IK 1991 Regulation of plasminogen activator activity in arthritic joints. J Rheumatol 18 Suppl 27: 106-109
12. Hamilton J A 1982 Plasminogen activator activity of rheumatoid and nonrheumatoid synovial fibroblasts. J Rheumatol 9: 834-842
13. Gonzalez-Gronow M, Gawdi G, Pizzo S V 1994 Characterization of the plasminogen receptor of normal and rheumatoid arthritis human synovial fibroblasts. J Biol Cem 269: 4360-4366
14. Raisz L G 1990 The role of prostaglandins in the local regulation of bone remodelling. Prog Clin Biol Res 332: 195-203
15. Golding M B, Golding S R 1990 Skeletal tissue response to cytokines. Clin Orthop Rel Res 285: 245-278
16. Eggelmeijer F, Papapoulos S E, Westedt M L et al 1993 Bone metabolism in rheumatoid arthritis: Relation to disease activity. Br J Rheumatol 32: 387-391
17. Bowen B L Fauci A S In: Inflammation-Basic principles and clinical correlates 1993, 877-895. New York : Raven Press
18. Bromley M, Wooley D E 1984 Chondroclasts and osteoclasts at subchondral site of erosion in the rheumatic joint. Arthritis Rheum 27: 968-975
19. Collins A A, Chambers T J 1991 Effect of prostaglandins E1, E2 and F2 alpha on oseoclast formation in mouse bone marrow cultures. J Bone Miner Res 6: 157-164
20. Leloup G, Delaisse J M, Vaes G 1994 Relationship of the plasminogen activator/plasmin cascade to oseoclast invasion and mineral resorption in explanted fetal metatarsal bones. J Bone Miner Res 9: 891-902
21. De Bart A C W, Quax P H A, Löwik C W G M, Verheijen J H 1995 Regulation of plasminogen activation, matrix metalloproteinases and urokinase-type plasminogen activator mediated extracellular matrix degradation in human osteosarcoma cell line MG 63 by interleukin-1 alpha. J Bone Miner Res 10: 1374-1384
22. Ronday H K, Smits H H, Quax P H A et al Bone matrix degradation by the plasminogen activation system. Possible mechanism of bone destruction in arthritis, submitted for publication
23. Anderson G I, Allan E H, Zhou H, Heersche J N M, Martin T J 1995 Osteoclasts activated by lowered pH express urokinase receptor message and induce greater plasminogen activation. J Bone Miner Res 10 Suppl 2: S284
24. Hoekman K, Löwik C W G M, van de Ruit M, Bijvoet O L M, Verheijen J H, Papapoulos S E, 1992 The effect of tissue type-plasminogen activator (t-PA) on osteoclastic resorption in embryonic mouse long bone explants: A possible role for the growth factor domain of t-PA. Bone Miner 17: 1-13
25. Rao N K, Shi G-P, Chapman H A 1995 urokinase receptor is a multifunctional protein: influence of receptor occupancy on macrophage gene expression. J Clin Invest 96: 465-474
26. Poole A R 1991 In: McCarthy D, Koopman W ,eds. Arthritis and allied conditions. A textbook of rheumatology. 12 edn 1991: 279-333 Philadelphia: Lea and Febiger
27. Collier S, Ghosh P 1988 The role of plasminogen in interleukin-1 mediated cartilage degradation. J Rheumatol 15: 1129-1137
28. Campbell I K, Piccolli D S, Butler D M, Singleton D K, Hamilton J A 1998 Recombinant human interleukin-1 stimulates human articular cartilage to undergo resorption and human chondrocytes to produce both tissue and urokinase-type plasminogen activator. Biochem Biophys Acta 967:183-194
29. Murphy G, Ward R, Gavrilovic J, Atkinson S 1992 Physiological mechanisms for metallo proteinase activation. Matrix suppl. 224-230
30. Keski-Oja J, Lohi J, Tuutila A, Tryggvason K, Vartio T 1992 Proteolytic processing of the 72.00 Da type IV collagenase by uokinase plasminogen activator. Exp Cell Res 202: 471-476
31. Fosang A J, Neame P J, Last K, Hardingham T E, Murphy G, Hamilton J A 1992 The interglobular domain of cartilage aggrecan is cleaved by PUMP, gelatinases and cathepsin B. J Biol Chem 267: 19470-19474
32. Kobayashi H, Schmitt M, Goretzki L et al 1991 Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (u-PA). J Biol Chem 266: 5147-5152
33. Stevens P, Scott R W, Shatzen E M 1993 Recombinant human protease nexin-1 prevents articular cartilage degradation in the rabbit. AAS. Joint Destruction in Arthritis and Osteoarthritis. 173-176 Basel: Birkhäuser Verlag
34. Nilsson I M 1979 Clinical pharmacology of aminocaproic and tranexamic acids. J Clin Pathol 33 (Suppl 24): 41-47
35. Butler M, Colombo C, Hickman L et al 1983 A new model of osteoarthritis in rabbits III. Evaluation of anti-osteoarthritic effects of selected drugs administered intra-articularly. Arthritis Rheum 26: 1380-1386
36. Vignon E, Mathieu P, Bejui J et al 1991. Study of an inhibitor of plasminogen activator (Tranexamic acid) in the treatment of experimental osteoarthritis. J Rheumatol 18 (Suppl 27): 131-133
37. Poole A R, Dieppe P 1994 Biological markers in rheumatoid arthritis. Seminars in Arthritis and Rheuamtism 23 (Suppl 2): 17-31
38. Ronday H K, Greenwald R A, Moak S A, et al Effect of tranexamic acid on urinary crosslink excretion in arthritis, manuscript in preparation